Granted Patent
B2
US 10,407,390 · App. 15/663,761 · Granted Sep 10, 2019
Asymmetric ureas and medical uses thereof
Inventors:
Silvina Garcia Rubio (Princeton, NJ); Claudio Pietra (Como, IT); Claudio Giuliano (Como, IT); Zhigang Li (Shanghai, CN)
Assignee:
Helsinn Healthcare SA
C07D211/58A61K31/4468A61K31/4525A61K31/4545A61K31/5375C07D211/60C07D211/94C07D211/96C07D401/06C07D401/12C07D405/12C07D413/12
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general formula (I):
Claims (3)
1. 3-((S)-1-(2,3 -dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea (GA202), or a pharmaceutically acceptable salt thereof.
2. (S)-1-hydroxy-3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-(1-methylpiperidin-4-yl)urea (GA170), or a pharmaceutically acceptable salt thereof.
3. (S)-3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-hydroxy-1-(1-methylpiperidin-4-yl)urea (GA182), or a pharmaceutically acceptable salt thereof.
Assignments (3)
RELEASE OF SECURITY INTEREST
Recorded Sep 20, 2023
From: HAMILTON SA LLC
To: HELSINN HEALTHCARE SA; HELSINN THERAPEUTICS (U.S.), INC.; HELSINN BIREX PHARMACEUTICALS LIMITED
Reel/Frame 064961/0567 →
SECURITY INTEREST
Recorded Dec 30, 2022
From: HELSINN HEALTHCARE SA; HELSINN THERAPEUTICS (U.S.), INC.; HELSINN BIREX PHARMACEUTICALS LIMITED
To: HAMILTON SA LLC
Reel/Frame 062254/0888 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 31, 2017
From: RUBIO, SILVINA GARCIA; PIETRA, CLAUDIO; GIULIANO, CLAUDIO; LI, ZHIGANG
To: HELSINN HEALTHCARE SA
Reel/Frame 043144/0819 →
Priority Claims (1)
WO PCT/CN2011/000298
· Feb 25, 2011
· international
Continuity (4)
Provisional Application
61466070
· Mar 22, 2011